Comparator Sourcing Risk in Global Clinical Trials
Comparator Sourcing Risk Increases as Studies Progress.
When sourcing strategy begins during study planning, risks remain manageable. When engagement occurs later, around study start, FPI, or enrollment peak - supply disruption can escalate across the clinical trial supply chain.
What Happens When Comparator Sourcing Begins Too Late?
When sourcing begins closer to study start or enrollment, supply risk increases significantly. Sponsors may face:
Limited or unavailable supply
Emergency sourcing
Premium pricing
Increased audit and compliance exposure
Timeline jeopardy
Because comparator sourcing issues rarely occur in isolation, these challenges can cascade across the clinical trial supply chain, impacting timelines, cost control and overall study continuity.
Figure 1: The Comparator Sourcing Risk Curve
The Comparator Sourcing Risk Curve illustrates how supply risk increases as sourcing engagement is delayed, while early engagement during study planning enables sourcing strategy, access mapping, regulatory pathways, supply chain design, and contingency planning.
How Do You Reduce Comparator Supply Risk?
Engaging Tanner Pharma early supports sourcing strategy, global sourcing capability, supplier governance and documentation control under a global QMS.
By integrating comparator sourcing into the clinical trial supply chain during study planning, sponsors can reduce supply disruption and support more predictable global study execution.